Renal cancer in von Hippel-Lindau disease and related syndromes

Nature Reviews Nephrology

Volumn 9, Issue 9, 2013, Pages 529-538

  Bausch, Birke ^a   Jilg, Cordula ^a   Gläsker, Sven ^a   Vortmeyer, Alexander ^b   Lützen, Niklas ^a   Anton, Alexandra ^a   Eng, Charis ^c   Neumann, Hartmut P H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b YALE UNIVERSITY   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER PREVENTION; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FAMILIAL CANCER; HUMAN; KIDNEY CARCINOMA; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VON HIPPEL LINDAU DISEASE;

EARLY DIAGNOSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; PRIMARY PREVENTION; PROGNOSIS; SYNDROME; VON HIPPEL-LINDAU DISEASE; WORLD HEALTH;

EID: 84883183489     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.144     Document Type: Review

References (87)

1. Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781 (2010).
2. Chow, W. H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
3. Linehan, W. M, Yang, J. C. & Bates, S. E. Cancer of the kidney. In Cancer: Principles & Practice of Oncology (eds DeVita, S. E., Hellman, S. & Rosenberg, S. A.) 1139-1168 (Lippincott Williams & Wilkins, 2005).
4. Tosco, L., Van Poppel, H., Frea, B., Gregoraci, G. & Joniau, S. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur. Urol. 63, 646-652 (2013).
5. Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
6. Linehan, W. M., Walther, M. M. & Zbar, B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163-2172 (2003).
7. Axwijk, P. H. et al. Hereditary causes of kidney tumours. Eur. J. Clin. Invest. 40, 433-439 (2010).
8. Bodmer, D. et al. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am. J. Hum. Genet. 62, 1475-1483 (1998).
9. Carpten, J. D. et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676-680 (2002).
10. Cohen, A. J. et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301, 592-595 (1979).
11. Malchoff, C. D. et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1758-1764 (2000).
12. Malinoc, A. et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr. Relat. Cancer 19, 283-290 (2012).
13. Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157-164 (2002).
14. Ricketts, C. et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst. 100, 1260-1262 (2008).
15. Ricketts, C. J. et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum. Mutat. 31, 41-51 (2010).
16. Ricketts, C. J. et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J. Urol. 188, 2063-2071 (2012).
17. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997).
18. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
19. Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153-159 (2004).
20. Choyke, P. L. et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am. J. Roentgenol. 159, 1229-1234 (1992).
21. Lonser, R. R. et al. von Hippel-Lindau disease. Lancet 361, 2059-2067 (2003).
22. Neumann, H. P. et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J. Urol. 160, 1248-1254 (1998).
23. Poston, C. D. et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J. Urol. 153, 22-26 (1995).
24. Gill, A. J. et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am. J. Surg. Pathol. 35, 1578-1585 (2011).
25. Wilding, A. et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J. Med. Genet. 49, 264-269 (2012).
26. Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994).
27. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
28. Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
29. Maher, E. R. et al. Von Hippel-Lindau disease: a genetic study. J. Med. Genet. 28, 443-447 (1991).
30. Neumann, H. P. & Wiestler, O. D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337, 1052-1054 (1991).
31. Maher, E .R. et al. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77, 1151-1163 (1990).
32. Maddock, I. R. et al. A genetic register for von Hippel-Lindau disease. J. Med. Genet. 33, 120-127 (1996).
33. Maher, E. R. & Kaelin, W. G. Jr. von Hippel-Lindau disease. Medicine (Baltimore) 76, 381-391 (1997).
34. Glasker, S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam. Cancer 4, 37-42 (2005).
35. Kreusel, K. M. Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam. Cancer 4, 43-47 (2005).
36. Kreusel, K. M., Bechrakis, N. E., Krause, L., Neumann, H. P. & Foerster, M. H. Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study. Ophthalmology 113, 1418-1424 (2006).
37. Walther, M. M., Lubensky, I. A., Venzon, D., Zbar, B. & Linehan, W. M. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154, 2010-2014 (1995).
38. Montani, M. et al. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am. J. Surg. Pathol. 34, 806-815 (2010).
39. Thoma, C. R. et al. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat. Cell Biol. 9, 588-595 (2007).
40. Jilg, C. A. et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urol. Int. 88, 71-78 (2011).
41. Walther, M. M. et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J. Urol. 161, 1475-1479 (1999).
42. Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002).
43. Akcaglar, S., Yavascaoglu, I., Vuruskan, H. & Oktay, B. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis. Int. Urol. Nephrol. 40, 615-620 (2008).
44. Hes, F. et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum. Genet. 106, 425-431 (2000).
45. Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673-682 (2002).
46. Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348-357 (1996).
47. Maranchie, J. K. et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum. Mutat. 23, 40-46 (2004).
48. McNeill, A. et al. Genotype-phenotype correlations in VHL exon deletions. Am J. Med. Genet. A 149A, 2147-2151 (2009).
49. Bayley, J. P. et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 11, 366-372 (2010).
50. Hao, H. X. et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139-1142 (2009).
51. Mannelli, M. et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J. Med. Genet. 44, 586-587 (2007).
52. Neumann, H. P. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459-1466 (2002).
53. Neumann, H. P. et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292, 943-951 (2004).
54. Schiavi, F. et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294, 2057-2063 (2005).
55. Bausch, B., Borozdin, W. & Neumann, H. P. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N. Engl. J. Med. 354, 2729-2731 (2006).
56. Merino, M. J., Parillar-Castella, E. R., Linehan, M. The unrecognised morphology of renal tumours in SDH syndromes: immunohistochemistry and genetic changes [abstract]. Mod. Pathol. 23, 917 (2010).
57. Gill, A. J. et al. Renal tumors and hereditary pheochromocytoma- paraganglioma syndrome type 4. N. Engl. J. Med. 364, 885-886 (2011).
58. Grubb, R. L. 3rd et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol. 177, 2074-2079 (2007).
59. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
60. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
61. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
62. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85 (2005).
63. Li, L. & Kaelin, W. G. Jr. New insights into the biology of renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25, 667-686 (2011).
64. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
65. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
66. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
67. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
68. Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F. & Wilt, T. J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 108, 1556-1563 (2011).
69. Guethmundsson, E., Hellborg, H., Lundstam, S., Erikson, S. & Ljungberg, B. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur. Urol. 60, 975-982 (2011).
70. Johnson, A. et al. Feasibility and outcomes of repeat partial nephrectomy. J. Urol. 180, 89-93 (2008).
71. Herring, J. C. et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J. Urol. 165, 777-781 (2001).
72. Duffey, B. G. et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J. Urol. 172, 63-65 (2004).
73. Ploussard, G. et al. Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. Urology 70, 435-439 (2007).
74. Matin, S. F., Ahrar, K., Wood, C. G., Daniels, M. & Jonasch, E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int. 102, 940-945 (2008).
75. Joly, D. et al. Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease. J. Urol. 185, 2056-2060 (2011).
76. Jilg, C. A. et al. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up. Fam. Cancer 11, 387-394 (2012).
77. Roupret, M. et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience. J. Urol. 170, 1752-1755 (2003).
78. Gupta, G. N. et al. Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. J. Urol. 184, 59-63 (2010).
79. Park, S. Y. et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery. Acta Radiol. 52, 680-685 (2011).
80. Iwamoto, Y. et al. Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results. Fam. Cancer 10, 529-534 (2011).
81. Park, B. K. & Kim, C. K. Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results. J. Urol. 183, 1703-1707 (2010).
82. Goldfarb, D. A., Neumann, H. P., Penn, I. & Novick, A. C. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 64, 1726-1729 (1997).
83. Atkins, M. B. Management of advanced renal cancer. Kidney Int. 67, 2069-2082 (2005).
84. Motzer, R. J. & Basch, E. Targeted drugs for metastatic renal cell carcinoma. Lancet 370, 2071-2073 (2007).
85. Motzer, R. J. et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 178, 1883-1887 (2007).
86. Shuin, T. et al. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn. J. Clin. Oncol. 36, 337-343 (2006).
87. Hensen, E. F. et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23, 4076-4083 (2004).